Dimin Zhu

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis.

Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis.

Journal: Journal of neuro-oncology

Published: November 03, 2025

circOMA1 delivered by exosomes regulates DRD2‑mediated prolactinoma resistance.

circOMA1 delivered by exosomes regulates DRD2‑mediated prolactinoma resistance.

Journal: International journal of molecular medicine

Published: October 11, 2025

Clinical application of combination [11C]C-methionine and [13N]N-ammonia PET/CT in recurrent functional pituitary adenomas with negative MRI or [18F]F-FDG PET/CT.

Clinical application of combination [11C]C-methionine and [13N]N-ammonia PET/CT in recurrent functional pituitary adenomas with negative MRI or [18F]F-FDG PET/CT.

Journal: BMC endocrine disorders

Published: June 29, 2023

Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.

Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly.

Journal: Journal of neurosurgery

Published: April 19, 2023

Feasibility analysis of ACTH adenoma model in USP8-/- mice.

Feasibility analysis of ACTH adenoma model in USP8-/- mice.

Journal: Endokrynologia Polska

Published: September 16, 2022

Prevalence and clinical characteristics of Crooke's cell adenomas in 101 patients with T-PIT-positive pituitary adenomas: Case series and literature review.

Prevalence and clinical characteristics of Crooke's cell adenomas in 101 patients with T-PIT-positive pituitary adenomas: Case series and literature review.

Journal: Frontiers in endocrinology

Published: May 18, 2022

Common tools for pituitary adenomas research: cell lines and primary cells.

Common tools for pituitary adenomas research: cell lines and primary cells.

Journal: Pituitary

Published: November 16, 2019

MiR-1299 promotes the synthesis and secretion of prolactin by inhibiting FOXO1 expression in drug-resistant prolactinomas.

MiR-1299 promotes the synthesis and secretion of prolactin by inhibiting FOXO1 expression in drug-resistant prolactinomas.

Journal: Biochemical and biophysical research communications

Published: September 05, 2019

MEG3/MIR-376B-3P/HMGA2 axis is involved in pituitary tumor invasiveness.

MEG3/MIR-376B-3P/HMGA2 axis is involved in pituitary tumor invasiveness.

Journal: Journal of neurosurgery

Published: July 21, 2019

Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study.

Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study.

Journal: Therapeutics and clinical risk management

Published: January 16, 2019

miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma.

miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma.

Journal: Brain research bulletin

Published: December 26, 2018

circOMA1-Mediated miR-145-5p Suppresses Tumor Growth of Nonfunctioning Pituitary Adenomas by Targeting TPT1.

circOMA1-Mediated miR-145-5p Suppresses Tumor Growth of Nonfunctioning Pituitary Adenomas by Targeting TPT1.

Journal: The Journal of clinical endocrinology and metabolism

Published: August 27, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026